Non disponible en dehors du Royaume-Uni et de l'Irlande
Analysis Note
ControlTF-1 cells
Application
This Milli-Mark Anti-CD41-FITC Antibody, clone 5B12 is validated for use in FC for the detection of CD41.
Research Sub CategoryImmunoglobulins & Immunology
Research CategoryInflammation & Immunology
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
CD41 is the α-subunit of the CD41/CD61 complex (GPIIb-IIIa), a calcium-dependent, non-covalently associated heterodimer. CD41 is a 135 kDa molecule, consisting of 2 peptides: a 120 kDa α chain and a 23 kDa β chain. The α chain and the β chain are linked by a single disulphide bond. The α chain contains four calcium-binding sites and is entirely extracellular, while the β-chain has extracellular, transmembrane, and cytoplasmic domains (Sun, 1997). The CD41/CD61 complex appears early in megakaryocyte maturation (Vinci, 1984). Anti-CD41, 5B12, was included in the Fifth International Workshop and Conference on Human Leukocyte Differentiation Antigens and studies by a number of laboratories confirmed its reactivity with CD41 (Honda, 1995).
Immunogen
Normal human platelets
Legal Information
MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany
Physical form
Protein A purified
Purified Mouse monoclonal IgG1 conjugated to FITC in 0.05M Tris-HCl buffer with 1% BSA, Sodium Azide at 0.097% at pH 7.2.
Quality
Evaluated by flow cytometry using TF-1 cells
Specificity
Antibody recognizes Human CD41 antigen.
Storage and Stability
Maintain refrigerated at 2-8°C protected from light in undiluted aliquots for up to 6 months from date of receipt.
Target description
135 kDa (Sun, 1997)
Ce produit répond aux critères suivants: